CJC-1295 (also known as CJC-1295 or DAC:GRF) is a therapeutically researched peptide studied for its effects on growth hormone, GHRH, subcutaneous. GHRH analog with extended half-life (6-8 days with DAC). 2-10x GH increase for 6+ days. Synergistic with Ipamorelin (3-5x boost via dual receptor targeting). Phase 2 trials discontinued after death. Cardiovascular risks. Not FDA-approved.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and growth hormone secretagogue developed by ConjuChem Biotechnologies. Two distinct forms exist: CJC-1295 WITH DAC (Drug Affinity Complex) features covalent albumin binding extending half-life to 5.8-8.1 days, while CJC-1295 WITHOUT DAC (Modified GRF 1-29) has 30-minute to 2-hour half-life requiring multiple daily doses. WITH DAC version binds to GHRH receptors in pituitary, activating G-proteins and increasing cAMP/IP3 production, resulting in 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days after single injection.
Overview
After multiple doses, IGF-1 remains elevated for 28 days.
Phase 2 clinical trials for HIV-associated lipodystrophy and growth hormone deficiency showed sustained, dose-dependent GH/IGF-1 increases with good tolerability at 30-60 mcg/kg doses.
Synergistic effects with Ipamorelin: Research indicates combining CJC-1295 with Ipamorelin produces enhanced GH release compared to either peptide alone.
CJC-1295 (GHRH analog) and Ipamorelin (selective GHRP mimicking ghrelin) target different receptor families in the pituitary, creating complementary stimulation—CJC-1295 provides sustained GH release while Ipamorelin induces rapid GH spikes.
Similar peptide combinations (GHRH analog + GHRP-2) showed synergistic interaction: individual compounds produced 20-fold and 47-fold GH increases respectively, but simultaneous application achieved 54-fold increase.
Clinical practitioners report the combination typically produces 3-5 fold increase in GH release versus monotherapy, though this specific claim for CJC-1295/Ipamorelin lacks published human trial verification.
The dual-action mechanism may enhance muscle mass, fat metabolism, recovery, and sleep quality.
Development discontinued following patient death during trials (attributed to unrelated coronary artery disease), though research terminated as precaution.
Critical safety concerns include cardiovascular risks: FDA warns of increased heart rate, systemic vasodilation, flushing, transient hypotension.
Elevated GH/IGF-1 can cause cardiac hypertrophy, fluid retention, increased blood pressure, particularly dangerous for pre-existing cardiovascular conditions.
Not FDA-approved; classified as Investigational New Drug available only for research.
Removed from FDA Category 2 list September 2024, making it eligible for Pharmacy Compounding Advisory Committee review.
Banned by WADA for competitive sports.
DAC version typically dosed 1-2x weekly, non-DAC version requires daily or twice-daily dosing.
Mechanism of action
Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.
Reported effects
Effects reported in the literature and from preclinical models include:
- Single subcutaneous injection produces dose-dependent 2-10 fold increases in mean plasma GH sustained for 6 or more days in healthy adults [1] Phase II
- Single injection raises mean plasma IGF-1 by 1.5-3 fold for 9-11 days, with cumulative multi-dose administration keeping IGF-1 above baseline for up to 28 days [1] Phase II
- Estimated plasma half-life of 5.8-8.1 days supports weekly or biweekly subcutaneous dosing, with no serious adverse reactions and good tolerability at 30-60 mcg/kg [1] Phase II
- Administration in healthy adult men produces measurable serum protein changes, including decreased apolipoprotein A1 and transthyretin isoforms, with an upregulated protein spot correlating with IGF-1 levels as potential GH-action biomarkers [2] Phase I
- CJC-1295 remains an investigational growth hormone secretagogue with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions; clinical use is not recommended outside rigorously designed research protocols [3][4] Anecdotal
Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal
Dosage and administration
CJC
- 1295 WITH DAC: 30-60 mcg/kg once or twice weekly (clinical trial dose)
- 1295 WITH DAC: 1-2mg per week (typical subcutaneous dose)
- 1295 WITHOUT DAC (Modified GRF 1-29): 100-200mcg 1-3x daily
WITHOUT DAC
- Requires daily or twice-daily dosing due to 30min-2hr half-life
WITH DAC
- Weekly dosing sufficient due to 6-8 day half-life
General
- Stack with GHRP peptides (e.g., Ipamorelin) for synergistic effects
- Cardiovascular screening required before use
Not recommended for those with pre
- existing heart conditions
Natty status
CJC-1295 is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[5]
Research
The peptide has been the subject of 8 studies and reference works collected on this site. The full bibliography is in § External links below.
Related compounds
Other peptides in this catalogue with overlapping mechanisms or status:
References
- a b c Phase 2 clinical trial efficacy results
- ^ Proteomic changes study
- ^ Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. Recent review
- ^ Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Recent review
- a b World Anti-Doping Agency. (2026). Prohibited List 2026.
External links
- Wikipedia article
- Animal model efficacy research
- Doping control detection methods
- GHRH detection methods
- CJC1295/Ipamorelin — commercial
- Bacteriostatic Water Reconstitution Solution 10ml — commercial
This page was last edited on June 3, 2026, at 14:56 (UTC).
Research last reviewed on June 3, 2026.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.